Overview

Tear Fluid Levels of Loteprednol Etabonate Ophthalmic Gel 0.5% Following a Single Instillation

Status:
Completed
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
To assess the levels of loteprednol etabonate (LE) in tear fluid following a single topical instillation of LE ophthalmic gel 0.5% formulation to healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Bausch & Lomb Incorporated
Treatments:
Loteprednol Etabonate